Booking Holdings Inc (NASDAQ:BKNG) is identified as a strong growth stock with a favorable technical setup, combining robust core business qualities with positive price trends. The company exhibits outstanding growth measures, high earnings, good financial condition, and an attractive price assessment, suggesting it is undervalued despite its strong performance. Additionally, recent price chart analysis indicates a potential shift with consolidation and emerging positive indicators after a significant drop, hinting at a possible upward movement.

Three financial company analysts issued bullish sentiments for Reinsurance Group (RGA), Willis Towers Watson (WTW), and Travelers Companies (TRV). Evercore ISI analyst Thomas Gallagher maintained a Buy rating for RGA with a $264.00 price target, while David Motemaden of Evercore ISI also maintained a Buy rating for WTW with a $390.00 price target. Roth MKM analyst Harry Fong maintained a Buy rating for TRV, which has a moderate buy consensus rating and an average price target of $307.79.

This TradingView page provides detailed options volatility data for Amrize Ltd (AMRZ) on the New York Stock Exchange. It features implied volatility curves for various expiration dates and highlights at-the-money (ATM) implied volatility to help users assess market risks and formulate options strategies. The page serves as a resource for traders looking to analyze market sentiment for AMRZ options.

AECOM (ACM) has partnered with Southern Methodist University (SMU) to create an AI fellowship program focused on advanced research, workforce development, and talent in infrastructure engineering. While this collaboration signals AECOM's long-term innovation strategy by building AI skills for future project execution, it doesn't immediately alter discussions around the company's current backlog challenges, high debt, and uneven free cash flow. Investors are encouraged to consider this AI initiative within the broader context of AECOM's financial health, growth forecasts, and analyst projections for margin improvement.

Zentalis Pharmaceuticals has selected a 400mg once-daily regimen for azenosertib as the optimal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer, based on interim analysis from the DENALI Phase 2 trial. This decision is crucial for their potential accelerated approval pathway, aligning both ongoing DENALI and planned ASPENOVA trials. The company's investment narrative heavily relies on azenosertib's success, with a topline readout expected by year-end 2026, though Zentalis remains loss-making with a volatile stock.

JPMorgan Chase & Co. has reduced its stake in Dingdong (Cayman) Limited by 47.4% in the third quarter, selling 459,095 shares and retaining 509,310 shares valued at approximately $1.05 million. Meanwhile, other institutional investors like Vanguard Group, Qube Research & Technologies, Man Group, Bank of America, and GSA Capital increased their positions in the company. Currently, institutional investors collectively own about 24.66% of Dingdong (Cayman), and analysts have an average "Hold" rating on the stock, which is trading near $2.68 with a market cap of around $632 million.

JPMorgan Chase & Co. reduced its stake in Tyra Biosciences, Inc. by 27.9% in the third quarter, now holding 74,229 shares valued at approximately $1.04 million. Other institutional investors like Federated Hermes Inc. and Russell Investments Group Ltd. increased their positions in the company. Tyra Biosciences has a "Moderate Buy" consensus rating from analysts with an average price target of $45.43.

Raleigh Capital Management Inc. reduced its stake in Johnson & Johnson by 26.9%, selling 4,297 shares and now holding 11,668 shares valued at $2.415 million. This makes J&J the firm's 29th largest holding, representing about 0.9% of its portfolio. Various analysts have raised price targets for J&J, with a consensus "Moderate Buy" rating, while insider selling totaling $7.36 million has been observed in the last 90 days.

JPMorgan Chase & Co. has acquired a new stake of 185,080 shares in Avino Silver & Gold Mines (NYSE:ASM), valued at approximately $972,000. Other institutional investors like VanEck, Mackenzie Financial Corp, Tidal Investments LLC, and Millennium Management LLC also significantly increased their positions, bringing total institutional ownership to 3.11%. Analysts currently rate ASM as a "Moderate Buy" with a consensus price target of $9.50, with one analyst raising their target to $12.50.

Raymond James Financial upgraded PTC Therapeutics (NASDAQ:PTCT) to a "moderate buy" rating, aligning with a MarketBeat consensus of "Moderate Buy" and an average analyst price target of $84.40. This upgrade comes despite PTC Therapeutics reporting a significant quarterly shortfall with an EPS of ($1.67) against an expected ($0.21) and revenue of $164.7 million versus $281.5 million, marking a 22.7% year-over-year decline. Company insiders have also recently been net sellers, with the CEO and VP selling approximately 124,666 shares totaling around $8.5 million in the last quarter, though insiders still hold about 5.50% of the stock.